WO2006018501A1 - Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques - Google Patents
Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques Download PDFInfo
- Publication number
- WO2006018501A1 WO2006018501A1 PCT/FR2005/001853 FR2005001853W WO2006018501A1 WO 2006018501 A1 WO2006018501 A1 WO 2006018501A1 FR 2005001853 W FR2005001853 W FR 2005001853W WO 2006018501 A1 WO2006018501 A1 WO 2006018501A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- excipients
- surfactants
- active ingredient
- application according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the subject of the invention is new galenic formulations for improving the intestinal absorption of orally active ingredients, their method of preparation and the application of lipid excipients associated with one or more surfactants and one or more co-surfactants to inhibit efflux pumps.
- the increase in absorption by a temporary change in the characteristics of the gastrointestinal tract involves: • either the use of absorption promoters that act via a paracellular pathway by opening a narrow junction (Liu, DZ et al. J. Pharm Sci 1999, 88 (11): 1161-1168, 1169-1174, Thanou, M. et al., J. Pharm Sci 2000, 90 (1): 38-46), or additives that inhibit esterases in the gastrointestinal tract, and thus increase the stability of the prodrug (Van Gelder, J et al., Pharm Res 1999, 16). (7): 1035-1040; Van Gelder, et al., Drug Metab Dispo. 2000, 28 (12): 1394-1396),
- the absorption of such active ingredients is significantly improved by the application of certain self-emulsifying mixtures of excipients for inhibiting efflux pumps.
- Novel pharmaceutical compositions comprising these mixtures have been used according to the invention.
- SEEDS Self-emulsifying Drug Delivery Systems
- SEEDS are solutions of oils and surfactants that form oil-in-water emulsions or microemulsions when they are placed in the presence of an aqueous medium.
- aqueous medium such as gastrointestinal fluid
- an inhibition of efflux pumps that increases the intestinal absorption of the active ingredient.
- the invention is therefore particularly applicable to active ingredients known to be poorly absorbed after oral administration and to be substrates of efflux pumps.
- This inhibition also leads, where appropriate, to an increase in the solubility and / or protection of the active ingredient against chemical degradation in the digestive tract.
- the result of the implementation according to the invention is a significant increase in intestinal absorption.
- the type of formulation according to the invention also makes it possible to reduce the doses compared to a conventional formulation for the same therapeutic efficacy, or even the same plasma exposure, which reduces the cost.
- the formulations according to the invention can also be applied to known and marketed active ingredients, thus making it possible to create new pharmaceutical forms which have increased intestinal absorption or to extend a product conventionally administered parenterally.
- the mechanism for promoting intestinal passage is due to an interaction of the excipient according to the invention with the biological system rather than an increase in solubility. Indeed, as shown in the experimental part as described below, the absorption is less than 1% when the active ingredient is prepared in DMSO for example, even though it is the solvent in which the solubility is the higher.
- the mechanism for promoting intestinal absorption of the systems according to the invention therefore involves the inhibition of an efflux pump such as P-glycoprotein. If necessary, it also involves increasing the solubility at physiological pH of the intestine and / or protection against degradation by digestive enzymes.
- the subject of the invention is therefore the application of self-emulsifying mixtures of lipid excipients and surfactants. and, where appropriate, co-surfactants, as defined below, to inhibit efflux pumps.
- the lipid excipients associated with one or more surfactants and, where appropriate, one or more co-surfactants in a self-emulsifying mixture act on one or more factors responsible for the poor absorption.
- compositions according to the present invention thus make it possible to improve the intestinal absorption of active principles having one or more of the following parameters. Opposing optimal absorption:
- the subject of the invention is the application of self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants, for the preparation of pharmaceutical compositions which can be administered orally and which contain one or more active ingredients, together with effect of increasing the intestinal absorption of said active ingredients by a mechanism involving the inhibition of efflux pumps.
- the invention also relates to the application of self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants, for the preparation of pharmaceutical compositions containing one or more active ingredients, with the effect of to increase the intestinal absorption of said active ingredients by a mechanism involving the inhibition of efflux pumps and the increase of the solubility of the active ingredient.
- the invention also relates to the application of self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants, for the preparation of pharmaceutical compositions containing one or more active ingredients, with the effect of to increase the intestinal absorption of said active ingredients by a mechanism involving the inhibition of efflux pumps and increasing the stability of the active principle in the gastrointestinal tract.
- the invention further relates to the application of self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants, for the preparation of pharmaceutical compositions containing one or more active ingredients, with the effect of to increase the intestinal absorption of said active ingredients by a mechanism involving the inhibition of efflux pumps, increasing the solubility of the active ingredient and increasing the stability of the active ingredient in the gastrointestinal tract.
- the invention more particularly relates to the use of self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants, in order to inhibit the activity of the P-glycoprotein.
- the active ingredient is in particular supported by P-glycoprotein and may be soluble or not soluble in the gastrointestinal tract, or stable or unstable in the gastrointestinal tract
- excipients and the choice of the ratios between these different excipients is carried out as follows: one of these excipients is a lipid excipient, and another excipient is a surfactant, and / or another excipient is a co-carrier. surfactant, and these excipients are added in a ratio such that, for a given active ingredient, the mixture forms a self-emulsifying system.
- the mixtures according to the invention may further comprise a solvent such as glycofurol or DMSO.
- self-emulsifying system is meant a liquid or solid solution formed of a lipid excipient, and optionally a surfactant which may be lipophilic (that is to say the hydrophilic-lipophilic balance [HLB] is greater than 10) or hydrophilic (HLB ⁇ 10) and / or a hydrophilic or lipophilic cosurfactant, which forms oil-in-water emulsions, with particle sizes between 0.1 and 10 ⁇ M, or microemulsions oil in water, with particle sizes below 100 nm, when added in an aqueous medium, directly or out of the physiological medium.
- a surfactant which may be lipophilic (that is to say the hydrophilic-lipophilic balance [HLB] is greater than 10) or hydrophilic (HLB ⁇ 10) and / or a hydrophilic or lipophilic cosurfactant, which forms oil-in-water emulsions, with particle sizes between 0.1 and 10 ⁇ M, or microemulsions oil in water, with particle sizes
- the subject of the invention is preferably self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants which form oil-in-water microemulsions when added to an aqueous medium, directly or outside the physiological milieu.
- the particles formed after interaction with an aqueous medium, and in particular the duodenal liquid have a size of less than 100 nm.
- lipid excipient in particular glycerides (mono-, di- and tri-glycerides), fatty acids and their derivatives, phospholipids, glycolipids and sterols.
- the lipid excipients are chosen from glycerides, fatty acids and their derivatives, phospholipids, glycolipids and sterols.
- lipid excipient preferably:
- glycerol monooleate as Peceol ® (Gattefosse)
- Glyceryl laurate such as Gelucire 44/14 ® (macrogol-32)
- polyglyceryl-3 oleate such as plurol oleic ® (Gattefossé)
- capric / caprylic / lauric acid triglycerides such as Captex 350 ® (Abitec Corporation)
- surfactant is meant an amphiphilic substance comprising two parts, one of hydrophobic character, the other of hydrophilic nature, and which acts at a water / lipid or water / air interface by lowering the interfacial tension, even at low concentration.
- the surfactant is lipophilic if HLB is greater than 10, hydrophilic if it is less than 10.
- the surfactant may in particular be hydrophilic.
- the surfactant may be lipophilic if appropriate.
- surfactant is preferably understood to mean
- co-surfactant a substance which has the properties of a surfactant, and which acts in the presence of a first surfactant by stabilizing the mixture formed by this surfactant and a lipid excipient.
- co-surfactant is preferably meant, according to the invention:
- Propylene glycol monocaprylate such as Capryol 90 ®
- the self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants are as follows:
- Transcutol ® / DMSO in proportions that can respectively vary between 50 and 60, 15 and 20, 15 and 20, and 5 and 15, or
- System 8 Soybean oil / Maisine 35-1 ® / Cremophor EL ® / Ethanol / Glycofurol, in proportions varying respectively between 25 and 35, 25 and 35, 25 and 35, 5 and 15, and 5 and 15,
- System 10 Soybean oil / Maisine 35-1 / Cremophor EL ® / Transcutol / Glycofurol, in proportions varying respectively between 25 and 35, 25 and 35, 25 and 35, 5 and 15, and 5 and 15 respectively.
- the self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants are in particular the following:
- System 11 Soybean / Maisine 35-1 ® / Cremophor EL ® / Transcutol ® / DMSO in proportions 27/27 / 28.8 / 7.2 / 10; • System 12: Soybean Oil / Maisine 35-1 ® /
- the invention also relates to pharmaceutical compositions comprising an active ingredient and a self-emulsifying mixture of lipid excipients, surfactants and, where appropriate, co-surfactants as defined above.
- compositions according to the invention are prepared in the following manner:
- compositions according to the invention can be in various forms depending on the case:
- the formulations according to the invention make it possible to increase the apparent permeability of an active ingredient in the AB direction (from the apical side to the basolateral side) and to decrease that in the BA direction (from the basolateral side to the apical side) compared with to a control formulation ( Figure 1, Appendix 1).
- the formulations according to the invention also increase the intracellular accumulation of an active ingredient relative to a control formulation ( Figure A 1 Appendix 1).
- excipients according to the invention can be used in injection to inhibit the P-glycoprotein of cancer cells to increase the cellular penetration of the active principle in tumor cells.
- the subject of the invention is therefore the application of self-emulsifying mixtures of lipid excipients, surfactants and, where appropriate, co-surfactants for the preparation of an injectable solution for inhibiting the P-glycoprotein of cells. cancerous and increase the cellular penetration of the active ingredient in tumor cells.
- Table 1 Formulations of molecule A used in the in vitro study.
- Table 2 Molecule A Formulations for the In Vivo Study in the Rat.
- the Caco-2 strains used in the tests are Caco-2 clone TC7 cells. This line is used to optimize the formulations and to investigate the absorption mechanism (s) in order to identify the parameter limiting the intestinal passage of active principles.
- solubility of molecule A is determined in purified water and in various buffers with pH values ranging from 1.2 to 8 (1.5, 2.5, 3.5, 4.5; 8, 6.8, 7.4 and 8.0)
- the suspensions are stirred for 24 hours at 25 ° C. and then centrifuged.
- the amount of molecule A in the supernatant is determined by HPLC, and the pH of the supernatant is checked.
- DMSO solutions are then diluted in 25mM HBSS / HEPES buffer (pH 7.4), in which 0.4 ⁇ Ci / ml of 14 C-mannitol or 0.4 ⁇ Ci / ml of 14 C-labeled molecule A was added (corresponding to 7 ⁇ M), so as to obtain final concentrations of molecule A of 7, 10, 50 or 100 ⁇ M.
- the final concentration of DMSO in each donor solution is adjusted to 0.5%.
- donor solutions containing 10 ⁇ M of molecule A and 100 ⁇ M of verapamil, nicardipine, or progesterone are prepared and the permeability of molecule A is evaluated and compared to that obtained without the P-glycoprotein modulator.
- the molecule A is dissolved in the macrogol 300 in order to obtain solutions of 0.3 ⁇ 10 -3 M or 10 -3 M. They are then diluted in HBSS / HEPES buffer, in which 0.4 ⁇ Ci / ml of 14 C-mannitol or 0.4 ⁇ Ci / ml of 14 C-labeled molecule A was added (see above) to obtain donor solutions whose final concentration in molecule A is 50 ⁇ M and the final macrogol content 300 in the donor solution of 5% •
- the control donor solution containing 0.5% DMSO and 5 ⁇ 10 -5 M of molecule A is prepared as indicated above.
- the various formulations are prepared by mixing, under the appropriate conditions, lipid excipients, surfactants and co-surfactants, followed by violent stirring for 30 seconds (Table 1). When semi-solid excipients are used, they are first dissolved in a water bath at 50 ° C.
- the molecule A is dissolved in DMSO or glycofurol, to obtain in each solvent solutions of concentrations of 4.3 ⁇ 10 -3 M or 5 ⁇ 10 -3 M.
- 40 ⁇ Ci / ml of molecule is added Labeled at 14 C in the solutions at 4.3 ⁇ 10 -3 M, so that the theoretical concentration in molecule A is 5 ⁇ 10 -3 M.
- the solutions at 5 ⁇ 10 -3 M are added with 40 ⁇ Ci / ml of 14 C-mannitol.
- Each of the solutions thus obtained is then diluted in the considered mixtures of lipid excipients and surfactants and, where appropriate, co-surfactants, giving formulations containing the solvent (DMSO or glycofurol) to
- the 14 C-labeled molecule A is injected into a 50/50 (v / v) mixture of glycofurol / water at a concentration of 1.5 mg / ml (145.9 ⁇ Ci / ml), which corresponds to the pharmacological dose.
- Glycofurol was chosen as the solvent allowing the administration of the desired amount of active ingredient, within the maximum volume that can be administered intravenously in the rat (1 ml / kg).
- the formulations are prepared as shown in Table 2.
- the 14 C-labeled molecule A (220 ⁇ Ci) is first dissolved in DMSO or glycofurol to obtain solutions at a final concentration of 5 mg / ml (488.9 ⁇ Ci / ml). These are then added in lipid mixtures to obtain the formulations described in Table 2, the final concentration of 14 C-labeled molecule A being 0.45 mg / ml.
- a control solution is prepared by dissolving the 14 C-labeled molecule A (220 ⁇ Ci) in the macrogol 300 at a final concentration of 0.5 mg / ml (44 ⁇ Ci / ml).
- the formulations are diluted in two volumes of water.
- the control solution of macrogol 300 is diluted in water so as to obtain a final concentration of 0.15 mg / ml (13.2 ⁇ Ci / ml).
- the formulations and the control thus prepared make it possible to administer to the rat 1.5 mg / kg in a volume of less than 10 ml / kg.
- passage cells 12 to 32 are deposited at a density of 5 x 10 5 cells / filter on 12 mm diameter polycarbonate filters in multi-well plates (Transwell®, Costar). The cells are incubated at 37 ° C. for 21 to 28 days, in complete medium supplemented with penicillin (100 IU / ml) and streptomycin (100 ⁇ g / ml) (Invitrogen).
- a set of 6 wells is used to determine the permeability values of molecule A (in the AB or BA direction) for each given solution.
- the basolateral medium is replaced by fresh HBSS / HEPES buffer (1.5 ml) and the apical medium (0.5 ml) with the donor solution.
- the apical medium is replaced by fresh HBSS / HEPES buffer, the basolateral medium by the donor solution.
- a control formulation of 50 ⁇ M molecule A in HBSS / HEPES buffer containing 0.5% DMSO is added on the basolateral side, and Control solution is added on the apical side.
- the samples are measured by counting ⁇ -scintillation, after addition of a scintillation liquid, Aqueous Counting Scintillant (ACS, Amersham Buckinghamshire, UK), with quenching correction in single labeling mode (LKB Wallac 1214, Broma, Sweden).
- Aqueous Counting Scintillant ACS, Amersham Buckinghamshire, UK
- quenching correction in single labeling mode
- the confluence of the Caco-2 is verified by measuring the value of the transepithelial electrical resistance using an endhom (WPI) provided with planar electrodes. This value is of the order of 360 ⁇ .cm 2 for confluent Caco-2 cell monolayers. For transport experiments, only confluent and differentiated Caco-2s are used.
- WPI endhom
- the integrity of the monolayer is checked again by measuring the value of the transepithelial electrical resistance. It is considered that the membrane integrity of the Caco-2 monolayer is compromised when the transepithelial electrical resistance value decreases by more than 25% and the apparent permeability to mannitol is greater than 10 ⁇ 6 cm / s.
- dQ represents the amount of active ingredient (counts / min) accumulated in the recipient compartment during the time interval dt, and A is the exposed surface of the monolayer (1.13 cm 2 ).
- Ci is the number of strokes / ml initial in the donor medium.
- the extrapolated absorbed fraction is calculated for transport studies in the AB direction, assuming neither the solubility, dissolution rate, efflux mechanism, nor stability in the gastrointestinal tract are formed. barrier for oral absorption.
- the intracellular accumulation of molecule A is evaluated in parallel with transport studies in AB and BA directions, using either a control donor formulation or a donor solution containing formulation B, each of these formulations containing the labeled molecule A at 14 C at 5 x 10 ⁇ 5 M.
- the basolateral side contains a control donor solution, and the apical side is filled by the placebo of Formulation B.
- a total of 24 wells are used for each formulation, in each direction.
- samples of the medium are taken, either on the apical side or on the basolateral, to determine the flux values (in DPM / cm 2 .h) in directions AB and BA, as described above.
- These filters which carry the Caco-2 cells, are introduced into a tube containing 1 ml of a 50/50 (vol / vol) mixture of HBSS / HEPES buffer and ethanol (95% vol).
- the liquid After resuspending the cells by sonication for 1 min, the liquid is centrifuged at 1000 g for 5 min.
- each cell forms a cylinder whose height is 17.9 ⁇ m and the diameter 13.3 ⁇ n ⁇ , and each monolayer contains 1.1 ⁇ 10 6 cells per cm 2 , as has been reported (Pontier et al., J. Pharm Sci 2001: 1608-1619).
- the apparent volume of the monolayers growing on a polycarbonate filter of 1.13 cm 2 is then 1.24 x 10 ⁇ 2 cm 3 .
- the average of the counts of the 6 corresponding wells is calculated.
- the flows J AB and J BA are both dependent on the intracellular C C AB and C C BA concentrations (expressed in DPM / cm 3 ) calculated from the intracellular accumulation experiments performed in parallel with the corresponding transport, in directions AB and BA respectively.
- the flows measured in the direction AB (J AB ) and in the direction BA (J BA ) are equal to the flows from the inside to the outside of the cell to the basolateral membrane (J CB ) and to the apical membrane (J CA ) respectively.
- Membrane permeabilities are calculated according to the equations:
- Papp CB and P ap p CA are mean membrane permeabilities in the CB and CA directions, respectively.
- Mean membrane permeability values are calculated using each of the 24 wells corresponding to the condition under study.
- Mean flow and mean intracellular concentration values are also calculated using each of the 24 wells corresponding to the condition being studied. The standard deviation of the population of 24 wells is also calculated. 1.6) Stability of the molecule A in the human duodenal fluid:
- the required volume of a sample of frozen human duodenal fluid is thawed immediately after collection. Centrifugation for 15 min at 1000 g removes mucus-like substances. The pH of the supernatant is adjusted by addition of MES buffer (1250 mM PBS CMF) at 6.40, a value close to the average pH value of the fresh duodenal fluid.
- Molecule A is dissolved in DMSO and diluted in HBSS / HEPES buffer (control) directly, or prepared in HBSS / HEPES dilution formulations to obtain a microemulsion.
- the final concentration in both cases is 10 -4 M.
- Formulations preheated to 37 ° C. are added to the duodenal fluid maintained at 37 ° C. in a ratio of 1/1 (v / v) and immediately mixed, so that the final concentration of the molecule A is 5.10 -5 M.
- samples of 100 ⁇ l of each preparation are taken and mixed with the same volume of acetone at 4 ° C. 0 C, to stop the enzymatic reaction.
- the samples are then centrifuged (1000 g for 5 min) and the supernatant tested by a validated LC / MS / MS method.
- each of the three tested formulations is mixed with 2 volumes of water and stirred violently, to obtain a homogeneous emulsion containing the molecule A at a concentration of 0.15 mg / ml.
- the final concentration in each of these formulations is identical to that of the PEG control formulation, that is to say 0.15 mg / ml (14.67 ⁇ Ci / ml).
- Each formulation is then administered to four groups of rats by gavage.
- the administration volume (10 ml / kg) is adjusted to body weight to have a dose of 1.5 mg / kg.
- Two other groups of animals receive the Glyc / w control solution through the tail vein at a dose of 1.5 mg / kg in a volume of 1 ml / kg.
- blood samples were collected by carotid incision at time 5 min (0.083 h).
- blood samples (0.2 ml) are collected at 0.25; 0.5; 1; 2 and 4 hours by retroorbital sampling; at 6 o'clock, the sample is taken by carotid incision.
- the samples are collected on tubes treated with lithium heparin and kept at 4 ° C.
- the plasma is separated from the whole blood by centrifugation at 2000 g for 10 min at 4 ° C.
- the radioactivity present in the plasma fractions is measured at scintillation counter.
- the concentration of 14 C-labeled molecule A in the plasma is expressed in mg.eq / l.
- AUC PO is the area under the plasma concentration curve from 0 to ⁇ hours after oral administration.
- AUC 1-v mean is the area under the concentration curve in 53
- the molecule A is subjected to an asymmetric transmission, with, depending on the concentration, P p P BA 15 to 24 times greater than P app AB ( Figure 1, Appendix 1).
- This effect is modulated by verapamil or nicardipine ( Figure 2, Appendix 1); it is therefore due to the action of the P-glycoprotein which opposes the trans-epithelial passage in the direction of the absorption of the molecule A.
- solubility of molecule A is low (0.4 mg / ml) in an aqueous medium at the physiological pH of the intestine.
- the solubility of the molecule A in aqueous solutions is very low at physiological pH (0.4 mg / ml).
- the solubility of molecule A is 6 mg / ml and 2 mg / ml, respectively.
- the stability of the A molecule in the human duodenal fluid was measured.
- 30% of the active ingredient is hydrolyzed after 120 minutes.
- 100% and 85% of the molecule A are still present with the formulations B and F, respectively.
- Table 4 Percentage of absorption (f p a '°) after oral administration of the formulations in rats.
- a formulation containing 1.7% of Gélucire 44 / 14® / Labrasol in proportions 80/20 in the transport medium allows to modulate the passage of the molecule B through the Caco-2 monolayers as follows:
- a molecule A permeability in both directions (AB and BA) in Caco-2 cell monolayers A molecule A permeability in both directions (AB and BA) in Caco-2 cell monolayers.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0513622-9A BRPI0513622A (pt) | 2004-07-27 | 2005-07-20 | aplicação de combinações auto-emulsificantes (seeds) de excipientes lipìdicos, de surfactantes; composição farmacêutica contendo um princìpio ativo e uma combinação auto-emulsificante (seeds) de excipientes lipìdicos, de surfactantes; e processo para a preparação de combinações auto-emulsificantes (seeds) de excipientes lipìdios, de surfactantes |
MX2007001141A MX2007001141A (es) | 2004-07-27 | 2005-07-20 | Aplicaciones galenicas de mezclas auto-emulsionantes de excipientes lipidicos. |
CA002579449A CA2579449A1 (fr) | 2004-07-27 | 2005-07-20 | Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques |
EP05790808A EP1771154A1 (fr) | 2004-07-27 | 2005-07-20 | Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques |
AU2005273839A AU2005273839A1 (en) | 2004-07-27 | 2005-07-20 | Galenic applications of self-emulsifying mixtures of lipidic excipients |
JP2007521988A JP2008508191A (ja) | 2004-07-27 | 2005-07-20 | 脂質賦形剤の自己乳化混合物のガレノス式適用 |
NZ552715A NZ552715A (en) | 2004-07-27 | 2005-07-20 | Galenic applications of self-emulsifying mixtures of lipidic excipients |
US11/572,402 US20080193519A1 (en) | 2004-07-20 | 2005-07-20 | Galenic Applications of Self-Emulsifying Mixtures of Lipidic Excipients |
IL180714A IL180714A0 (en) | 2004-07-27 | 2007-01-15 | Galenic applications of self-emulsifying mixtures of lipidic excipients |
NO20070354A NO20070354L (no) | 2004-07-27 | 2007-01-19 | Galeniske anvendelser om selvemulgerende blandinger av lipideksipienter |
US12/870,250 US20110104268A1 (en) | 2004-07-27 | 2010-08-27 | Galenic applications of self-emulsifying mixtures of lipidic excipients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0408269 | 2004-07-27 | ||
FR0408269A FR2873585B1 (fr) | 2004-07-27 | 2004-07-27 | Nouvelles formulations galeniques de principes actifs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/870,250 Continuation US20110104268A1 (en) | 2004-07-27 | 2010-08-27 | Galenic applications of self-emulsifying mixtures of lipidic excipients |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006018501A1 true WO2006018501A1 (fr) | 2006-02-23 |
WO2006018501A8 WO2006018501A8 (fr) | 2007-03-01 |
Family
ID=34951660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/001853 WO2006018501A1 (fr) | 2004-07-20 | 2005-07-20 | Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques |
Country Status (18)
Country | Link |
---|---|
US (2) | US20080193519A1 (fr) |
EP (1) | EP1771154A1 (fr) |
JP (1) | JP2008508191A (fr) |
KR (1) | KR20070046819A (fr) |
CN (1) | CN101001608A (fr) |
AU (1) | AU2005273839A1 (fr) |
BR (1) | BRPI0513622A (fr) |
CA (1) | CA2579449A1 (fr) |
FR (1) | FR2873585B1 (fr) |
IL (1) | IL180714A0 (fr) |
MA (1) | MA28748B1 (fr) |
MX (1) | MX2007001141A (fr) |
NO (1) | NO20070354L (fr) |
NZ (1) | NZ552715A (fr) |
RU (1) | RU2381789C2 (fr) |
TW (1) | TW200616640A (fr) |
WO (1) | WO2006018501A1 (fr) |
ZA (1) | ZA200700553B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867323A1 (fr) * | 2006-06-13 | 2007-12-19 | Farmatron Ltd. | Formulations pharmaceutiques avec pénétration améliorée à travers des barrières biologiques |
JP2010536826A (ja) * | 2007-08-21 | 2010-12-02 | バジリア ファルマスーチカ アーゲー | 抗真菌組成物 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2661812T3 (es) | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Composiciones |
JP2013209294A (ja) * | 2010-07-30 | 2013-10-10 | Meiji Seikaファルマ株式会社 | 液状医薬組成物 |
CA2856520C (fr) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Preparations et therapies de substitution pour hormonotherapie naturelle combinee |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
KR101542364B1 (ko) * | 2014-10-31 | 2015-08-07 | 대화제약 주식회사 | 탁산을 포함하는 경구 투여용 약학 조성물 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173044A1 (fr) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne |
CA3020153A1 (fr) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Composition pharmaceutique d'hormone steroide |
JP2022514991A (ja) * | 2018-12-10 | 2022-02-16 | ハロー・サイエンス・エル・エル・シー | 安定な麻酔薬製剤および関連する剤形 |
CZ309587B6 (cs) * | 2021-01-22 | 2023-05-03 | Oncora S.R.O. | Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy |
CN114246827B (zh) * | 2022-01-04 | 2023-04-11 | 中山大学 | 一种鱼油微乳制剂及其制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0414632A2 (fr) * | 1989-07-24 | 1991-02-27 | Sandoz Ltd. | Dérivés de cyclosporine |
FR2710535A1 (fr) * | 1993-09-30 | 1995-04-07 | Gattefosse Ets Sa | Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion. |
WO1999032457A1 (fr) * | 1997-12-19 | 1999-07-01 | Aventis Pharma Deutschland Gmbh | Nouveaux derives d'acylguanidine en tant qu'inhibiteurs de la resorption osseuse et qu'antagonistes du recepteur de vitronectine |
WO1999037621A1 (fr) * | 1998-01-23 | 1999-07-29 | Aventis Pharma Deutschland Gmbh | Nouveaux derives de sulfamide comme inhibiteurs de la resorption osseuse et comme inhibiteurs de l'adherence cellulaire |
WO1999049848A1 (fr) * | 1998-04-01 | 1999-10-07 | Rtp Pharma Inc. | Compositions anticancereuses |
WO2000003753A2 (fr) * | 1998-07-14 | 2000-01-27 | Em Industries, Inc. | Systemes d'apport de medicaments par microdispersion |
WO2001060827A1 (fr) * | 2000-02-17 | 2001-08-23 | University College Cardiff Consultants Limited | Nouveaux composes inhibiteurs de la glycoproteine p |
WO2002053131A1 (fr) * | 2000-12-28 | 2002-07-11 | Cll Pharma | Compositions pharmaceutiques colloïdales micellaires renfermant un principe actif lipophile |
WO2003011207A2 (fr) * | 2001-07-27 | 2003-02-13 | Gattefosse Holding | Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal |
WO2003045357A1 (fr) * | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Formules pharmaceutiques orales contenant du paclitaxel et des derives, et methodes d'administration de celles-ci |
WO2003095447A1 (fr) * | 2002-05-14 | 2003-11-20 | Xenova Limited | Procede de preparation d'un hydrate de derive d'acide anthranilique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054136A (en) * | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
-
2004
- 2004-07-27 FR FR0408269A patent/FR2873585B1/fr not_active Expired - Fee Related
-
2005
- 2005-07-20 KR KR1020077001445A patent/KR20070046819A/ko not_active Application Discontinuation
- 2005-07-20 CN CNA2005800268156A patent/CN101001608A/zh active Pending
- 2005-07-20 RU RU2007107199/15A patent/RU2381789C2/ru not_active IP Right Cessation
- 2005-07-20 WO PCT/FR2005/001853 patent/WO2006018501A1/fr active Application Filing
- 2005-07-20 NZ NZ552715A patent/NZ552715A/en not_active IP Right Cessation
- 2005-07-20 BR BRPI0513622-9A patent/BRPI0513622A/pt not_active IP Right Cessation
- 2005-07-20 EP EP05790808A patent/EP1771154A1/fr not_active Withdrawn
- 2005-07-20 JP JP2007521988A patent/JP2008508191A/ja active Pending
- 2005-07-20 US US11/572,402 patent/US20080193519A1/en not_active Abandoned
- 2005-07-20 CA CA002579449A patent/CA2579449A1/fr not_active Abandoned
- 2005-07-20 MX MX2007001141A patent/MX2007001141A/es not_active Application Discontinuation
- 2005-07-20 AU AU2005273839A patent/AU2005273839A1/en not_active Abandoned
- 2005-07-26 TW TW094125195A patent/TW200616640A/zh unknown
-
2007
- 2007-01-15 IL IL180714A patent/IL180714A0/en unknown
- 2007-01-19 ZA ZA200700553A patent/ZA200700553B/en unknown
- 2007-01-19 NO NO20070354A patent/NO20070354L/no not_active Application Discontinuation
- 2007-01-23 MA MA29627A patent/MA28748B1/fr unknown
-
2010
- 2010-08-27 US US12/870,250 patent/US20110104268A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0414632A2 (fr) * | 1989-07-24 | 1991-02-27 | Sandoz Ltd. | Dérivés de cyclosporine |
FR2710535A1 (fr) * | 1993-09-30 | 1995-04-07 | Gattefosse Ets Sa | Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion. |
WO1999032457A1 (fr) * | 1997-12-19 | 1999-07-01 | Aventis Pharma Deutschland Gmbh | Nouveaux derives d'acylguanidine en tant qu'inhibiteurs de la resorption osseuse et qu'antagonistes du recepteur de vitronectine |
WO1999037621A1 (fr) * | 1998-01-23 | 1999-07-29 | Aventis Pharma Deutschland Gmbh | Nouveaux derives de sulfamide comme inhibiteurs de la resorption osseuse et comme inhibiteurs de l'adherence cellulaire |
WO1999049848A1 (fr) * | 1998-04-01 | 1999-10-07 | Rtp Pharma Inc. | Compositions anticancereuses |
WO2000003753A2 (fr) * | 1998-07-14 | 2000-01-27 | Em Industries, Inc. | Systemes d'apport de medicaments par microdispersion |
WO2001060827A1 (fr) * | 2000-02-17 | 2001-08-23 | University College Cardiff Consultants Limited | Nouveaux composes inhibiteurs de la glycoproteine p |
WO2002053131A1 (fr) * | 2000-12-28 | 2002-07-11 | Cll Pharma | Compositions pharmaceutiques colloïdales micellaires renfermant un principe actif lipophile |
WO2003011207A2 (fr) * | 2001-07-27 | 2003-02-13 | Gattefosse Holding | Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal |
WO2003045357A1 (fr) * | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Formules pharmaceutiques orales contenant du paclitaxel et des derives, et methodes d'administration de celles-ci |
WO2003095447A1 (fr) * | 2002-05-14 | 2003-11-20 | Xenova Limited | Procede de preparation d'un hydrate de derive d'acide anthranilique |
Non-Patent Citations (4)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 18 June 2004 (2004-06-18), CORNAIRE GILLES ET AL: "Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo", XP002320289, Database accession no. PREV200400390658 * |
INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), vol. 278, no. 1, 18 June 2004 (2004-06-18), pages 119 - 131, ISSN: 0378-5173 * |
NERURKAR MANOJ M ET AL: "Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 86, no. 7, 1997, pages 813 - 821, XP002320288, ISSN: 0022-3549 * |
NERURKAR MANOJ M ET AL: "The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 13, no. 4, 1996, pages 528 - 534, XP009044856, ISSN: 0724-8741 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867323A1 (fr) * | 2006-06-13 | 2007-12-19 | Farmatron Ltd. | Formulations pharmaceutiques avec pénétration améliorée à travers des barrières biologiques |
WO2007144139A3 (fr) * | 2006-06-13 | 2008-03-13 | Farmatron Ltd | Compositions pharmaceutiques présentant des propriétés améliorant la pénétration de barrières biologiques |
JP2010536826A (ja) * | 2007-08-21 | 2010-12-02 | バジリア ファルマスーチカ アーゲー | 抗真菌組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR20070046819A (ko) | 2007-05-03 |
RU2381789C2 (ru) | 2010-02-20 |
CN101001608A (zh) | 2007-07-18 |
JP2008508191A (ja) | 2008-03-21 |
AU2005273839A1 (en) | 2006-02-23 |
US20110104268A1 (en) | 2011-05-05 |
MA28748B1 (fr) | 2007-07-02 |
TW200616640A (en) | 2006-06-01 |
NZ552715A (en) | 2010-12-24 |
CA2579449A1 (fr) | 2006-02-23 |
FR2873585A1 (fr) | 2006-02-03 |
IL180714A0 (en) | 2007-06-03 |
RU2007107199A (ru) | 2008-09-10 |
FR2873585B1 (fr) | 2006-11-17 |
BRPI0513622A (pt) | 2008-05-13 |
ZA200700553B (en) | 2008-05-28 |
US20080193519A1 (en) | 2008-08-14 |
WO2006018501A8 (fr) | 2007-03-01 |
EP1771154A1 (fr) | 2007-04-11 |
NO20070354L (no) | 2007-04-17 |
MX2007001141A (es) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006018501A1 (fr) | Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques | |
Li et al. | Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability | |
WO1996033697A1 (fr) | Formulation auto-emulsionnable formant une emulsion huile dans l'eau | |
EP1242047A1 (fr) | Formulations galeniques du fenofibrate et leur procede d'obtention | |
WO2010124525A1 (fr) | Composition pharmaceutique orale auto-micro-émulsifiante de médicament hydrophile et son procédé de préparation | |
EP1345590A1 (fr) | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile | |
WO1998043635A1 (fr) | Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino- 3-pyrazolecarboxamide, de ses sels et de leurs solvates | |
JP2002511099A (ja) | 親油性化合物用の自己乳化性処方 | |
CA2680433A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
Patel et al. | Novel drug delivery approach via self-microemulsifying drug delivery system for enhancing oral bioavailability of asenapine maleate: optimization, characterization, cell uptake, and in vivo pharmacokinetic studies | |
EP2637645B1 (fr) | Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation | |
EP0927026A1 (fr) | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques | |
WO2015022454A1 (fr) | Nouveau systeme solide instantane auto-emulsionnant a base de cyclodextrines et d'huile (s) pour l'administration orale | |
EP2315583B1 (fr) | Formulation destinée à améliorer la biodisponibilité d'une molécule hydrophobe | |
EP1244427B1 (fr) | Compositions pharmaceutiques destinees a une administration par voie orale | |
Sonawale et al. | Solubility enhancement of lipophilic drugs-solid self micro-emulsifying drug delivery system | |
KR20110046990A (ko) | 올메사르탄메독소밀 함유 자가유화 약물전달시스템 조성물 및 이의 제조방법 | |
WO2006070129A1 (fr) | Formulations injectables ou administrables par voie orale de derives d'azetidine | |
EP0726760B1 (fr) | Formulation auto-emulsionnable formant une huile dans eau | |
WO2004010977A1 (fr) | Procede pour diminuer la variabilite de la biodisponibilite d'un medicament a administration orale | |
Qader et al. | Novel oral solid self-nanoemulsifying drug delivery system (S-SNEDDS) of rosuvastatin calcium: Formulation, characterization, bioavailability and pharmacokinetic study | |
Yahaya et al. | Piroxicam-loaded self-emulsifying drug delivery system | |
CA2544413A1 (fr) | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3carboxamide | |
Panchal et al. | Self Emulsifying Drug Delivery System, A Novel Approach in Drug Delivery: A Review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 12007500118 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005273839 Country of ref document: AU Ref document number: 180714 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552715 Country of ref document: NZ Ref document number: 2007/00553 Country of ref document: ZA Ref document number: 1020077001445 Country of ref document: KR Ref document number: 200700553 Country of ref document: ZA Ref document number: 2007521988 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005790808 Country of ref document: EP Ref document number: 624/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07006741 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001141 Country of ref document: MX Ref document number: 2579449 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000062 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580026815.6 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005273839 Country of ref document: AU Date of ref document: 20050720 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005273839 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007107199 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005790808 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11572402 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0513622 Country of ref document: BR |